Bavarian Nordic A/S announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active i...
Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and sev...
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy ...
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis...
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development und...
Nxera Pharma Co., Ltd. announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli ...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio Silo Pharma, Inc. (Nasdaq: SILO...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES pha...
Global pharma major Lupin Limited (Lupin) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pha...
Symbiosis Pharmaceutical Services (Symbiosis), a Contract Development and Manufacturing Organisation (CDMO) specialising in the sterile GMP manufacturer ...
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmace...
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company w...
© 2026 Biopharma Boardroom. All Rights Reserved.
